Search PubMed⌕ Search

Biomedical subjects

P M Furneri

Publications and source records attributed to P M Furneri.

34 records · Page 2Linked to original sources
PubMed1991

Some pharmacokinetic data on miocamycin II. Concentrations in gynaecological tissues.

The gynaecological tissue levels of miocamycin were studied in ten female patients after pre-operative administration. The patients were divided into two groups on the basis of the scheduled sampling time. All the patients received 4200 mg of the drug, divided in 7 tablets of 600 mg each every 8 h, last administration 2 or 3 h before surgery. The tissue levels, obtained by means of the microbiological method (Sarcina lutea 9341), were frequently higher than those obtained in the serum at the same time. Miocamycin reached the highest concentration in the endometrium (2.5 micrograms/g) and the lowest in the vagina (1.1-0.8 micrograms/g).

Biological Assay↗
PubMed1989

Serum IgA antibodies in HSV asymptomatic genital infections.

Cervico-vaginal swabs and serum samples from 81 women without herpes-associated clinical symptoms were examined for virus isolation and for the presence of IgA antibodies to herpes simplex virus (HSV) using the indirect fluorescent antibody technique. Nineteen of the 81 women were followed up for 2 years. Blood samples and swabs from cutaneous lesions were obtained from another group of 20 women (medical staff) with herpes labialis. By analysing the specific anti-HSV IgA antibodies, a higher geometric mean titre (GMT) was found in women with positive HSV-2 isolation (GMT = 380.03), as opposed to the GMT observed in women with negative HSV-2 (GMT = 63.43) or positive HSV-1 isolation (GMT = 55.15). Results from the longitudinal study also demonstrated that positive virus isolation always correlated with a marked rise in serum IgA antibody to HSV.

Adolescent↗
PubMed1988

Efficacy of miocamycin in the therapy of non-specific genital infections (NSGI): non-gonococcal urethritis (NGU) and acute urethral syndrome (AUS).

The therapeutic efficacy of miocamycin against Ureaplasma urealyticum and Chlamydia trachomatis was the object of this study. Two different groups of patients were included in the trial: 40 males and 20 females affected by NGU and AUS respectively. All the patients positive for chlamydiae and/or ureaplasmas received 1200 mg/die of miocamycin for 12 days; a microbiological examination was performed 5 days from the end of the therapy. The therapy with miocamycin caused the resolution of both symptoms and microorganisms present. The use of miocamycin in current therapy could be favourable.

Acute Disease↗
PubMed1988

Some pharmacokinetic data on miocamycin. I: Serum, urinary and prostatic levels.

The pharmacokinetics of miocamycin were studied in ten healthy male volunteers after three different administrations: the first group received 600 mg in a single oral dose; the second received 1200 mg divided into two administrations of 600 mg, each one every 12 h; the third received 1200 mg in a single oral dose. Prostatic levels of miocamycin were recorded after the administration of 1200 mg, divided into two administrations of 600 mg every 12 h. The pharmacokinetic analysis was carried out by applying a single-compartment kinetic model with zero-order absorption. The apparent duration of absorption (T) was about 0.55 h for all subjects. The area under the curve was 7.5767 +/- 0.2511 mg/h/l in the first group; 6.7333 +/- 0.6058 mg/h/l in the second group; and 18.6825 +/- 15.1555 mg/h/l in the third. The prostatic levels were five times higher than those in the serum at the same time.

Adolescent↗
PubMed1987

Further characterization of the in vitro and in vivo activity of ciprofloxacin against mycoplasmas.

The aim of this study was the evaluation of some parameters which might better characterize ciprofloxacin: the influence of inoculum, serum and medium. Resistance development, hamster protection and mycoplasmacidal concentrations were also investigated. Ciprofloxacin showed moderate antimycoplasmal activity, both in vitro and in vivo. The minimum inhibitory concentrations (MICs) for Ureaplasma urealyticum, if compared to those shown by erythromycin, are lower, but higher than those obtained with tetracyclines. Unlike the macrolides, ciprofloxacin suffers from change of inoculum size, but no single step resistance induction was reported both in ureaplasmas and mycoplasmas. If Mycoplasma pneumoniae pneumonia or genital infections due to U. urealyticum carry out gram-negative rod isolation, ciprofloxacin can be considered a valid therapeutic agent for these mixed infections.

Animals↗
PubMed1987

Anti-mycoplasmal activity of a new macrolide: miocamycin.

The object of this study was the evaluation of the activity of miocamycin and other macrolides (erythromycin and josamycin) against 61 Ureaplasma urealyticum, 1 Acholeplasma laidlawii and 21 aerobe mycoplasmas (M. pneumoniae, M. hominis, M. gallisepticum, M. mycoides) and anaerobe mycoplasmas (M. morale and M. salivarium) both clinically isolated and standard reference strains. The minimum inhibitory concentrations (MIC) values for miocamycin ranged between 0.00625 mg/l and 0.4 mg/l (ureaplasmas) and between 0.001 mg/l and 0.0625 mg/l (mycoplasmas, except M. hominis with 0.025 mg/l to 0.25 mg/l). For erythromycin, the MIC values ranged between 0.19 mg/l up to 500 mg/l (ureaplasmas) and between 0.001 mg/l to 0.0625 mg/l (mycoplasmas, except M. hominis with 100 mg/l to 1000 mg/l). MIC values for josamycin ranged between 0.03125 mg/l and 0.5 mg/l (M. pneumoniae only). The sub-MIC treatment (carried out on human pathogenic mycoplasmas only) evidenced growth curve modifications and a decrease of the O2 uptake directly correlated to the drug concentrations.

Acholeplasma↗
PubMedDate not supplied

Inhibitory effects of 3-imino-5-phenyl-3H-1,2-dithiole on poliovirus type 1 replication in vitro.

The effect of 3-imino-5-phenyl-3H-1,2-dithiole (PDTI) on different steps of the replicative cycle of poliovirus type 1 in HEp-2 cells was studied. This compound inhibited the replication of poliovirus type 1 as shown by cytopathic effect and virus yield reduction. This inhibitory action was not due to a virucidal effect, nor did the cells to have been pretreated. Under one-step growth conditions 3-imino-5-phenyl-3H-1,2-dithiole caused the greatest inhibition if added within 1 h after poliovirus adsorption. [5-3H]uridine incorporation into RNA showed that PDTI reduced poliovirus RNA synthesis. In fact, in the presence of PDTI viral RNA synthesis was shut off completely at 2 h post infection, and at 4 h post infection viral RNA synthesis was reduced by 50%. The compound may have an inhibitory effect on the early transcriptional and/or replicative functions of the poliovirus genome.

Antiviral Agents↗
PubMedDate not supplied

In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis.

The in vitro activity of a new fluoroquinolone, rufloxacin, was determined against both clinical isolates and standard strains of Legionella pneumophila, Chlamydia trachomatis, and Listeria monocytogenes and compared to that of ciprofloxacin, ofloxacin, and erythromycin. Among the antibacterials tested erythromycin was the most active. Rufloxacin inhibited the growth of L. pneumophila at concentrations in the range of 0.06-0.25 mg/l, that of C. trachomatis at concentrations in the range of 2-4, and that of L. monocytogenes at concentrations in the range of 1-2 mg/l. Rufloxacin demonstrated approximately the same activity as ciprofloxacin against C. trachomatis, but twice as less potency as ofloxacin and erythromycin against L. pneumophila, L. monocytogenes, and C. trachomatis, and twice as less potency as ciprofloxacin against L. pneumophila.

Anti-Infective Agents↗
PubMedDate not supplied

C. trachomatis detection in infertile women by using a tubal cytobrush during laparoscopy.

The significant role played by C. trachomatis infection in tubal infertility has been emphasized by several serological studies, even if many problems related to the aetiologic diagnosis are still unsolved. For several months our routine screening of infertile women has included a non traumatic technique for tubal cell removal during laparoscopy by using a flexible "Fallopian tube brush". The method is suitable both for C. trachomatis isolation on MC Coy cell culture and rapid (4 hrs.), direct detection of C.t. antigens by immunofluorescent test; it rarely provokes bleeding, nor does it cause formation of adherences as later observed in patients who underwent further laparoscopy during GIFT/ZIFT. In addition, it furnished a mean of 50,000 cells/ml and finally removed samples not only from the tubal ostium, but also from the endosalpingeal lumen.

Adult↗
PubMedDate not supplied

Evaluation of antinfective activity of an association bifidobacterium/lactobacillus in mouse intestine.

The present research aimed at studying the action of an association of Bifidobacterium bifidum and Lactobacillus acidophilus, in controlling an experimental severe infection by Salmonella enteritidis administered in mouse per os. The behaviour of some parameters was undertaken, checking for the pH of intestinal content; the condition of the colonization in the intestinal wall by means of scanning electron microscopy and plates cultures; the presence of antibodies IgA in intestinal content; the index of mortality in the diversely treated animal's groups. The reported data show a string incidence of the administration of Bifidobacterium and Lactobacillus in increasing the animal's resistance against the lethal infection.

Animals↗